{"filings":[{"id":2172001,"accession_number":"0001213900-26-087506","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2026-08-11T12:05:36+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Q2 net loss $21.7M; guides ADVANCED-2 enrollment completion, THRIVE-3 interim results to 4Q 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss of $21.7M ($0.36/share) vs. $15.0M ($0.35/share) in Q2 2025.","Cash and equivalents of $161.9M at June 30, 2026; expected to fund operations into 2028.","ADVANCED-2 BCG-Unresponsive cohort enrollment completion expected 4Q 2026; ADVANCED-3 redesigned as exploratory trial.","STARBORN-1 showed 83% (10/12) clinical success, 100% (10/10) evaluable; BLA for TARA-002 in LMs expected 2H 2027.","R&D expenses rose to $17.0M from $10.8M YoY; THRIVE-3 interim results expected in 4Q 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1335316,"accession_number":"0001213900-26-073184","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2026-06-29T21:02:44+00:00","items":["5.02"],"status":"ready","headline":"Protara Therapeutics CMO Leonardo Viana Nicacio resigns effective June 26, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leonardo Viana Nicacio, M.D., resigned as Chief Medical Officer to pursue other opportunities.","Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, assumes his duties.","Jacqueline Zummo, Ph.D., Chief R&D Officer, will oversee the clinical development function.","Departure is effective June 26, 2026; no other officer changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1056488,"accession_number":"0001213900-26-068774","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2026-06-15T20:05:37+00:00","items":["5.07"],"status":"ready","headline":"Protara shareholders vote to double authorized shares to 200M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 100M to 200M shares; 42.4M for, 2.7M against.","Class III directors elected: Jesse Shefferman, Barry Flannelly, Cynthia Smith.","Advisory say-on-pay approved (29.2M for); frequency set to every 1 year (26.8M for).","Amendment to 2024 Equity Incentive Plan approved (18.1M for, 12.8M against).","Officer exculpation amendment passed (29.6M for, 1.2M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50447,"accession_number":"0001213900-26-055462","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2026-05-13T12:05:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 Programs in LMs and NMIBC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents and investments of $177.4 million as of March 31, 2026, expected to fund operations into 2028.","Net loss of $17.8 million ($0.31 per share) for Q1 2026, compared to $11.9 million loss in Q1 2025.","Intends to submit BLA for TARA-002 in Lymphatic Malformations in second half of 2027 based on STARBORN-1 trial.","Expects to complete enrollment of BCG-Unresponsive cohort in ADVANCED-2 trial and initiate ADVANCED-3 trial in BCG-Naïve patients in second half of 2026.","Updated interim safety and durability data from STARBORN-1 to be presented at ISSVA World Congress in May 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103235,"accession_number":"0001213900-26-035971","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Protara reports 68% six-month CR rate in TARA-002 trial; triggers warrant exercise period","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six-month complete response (CR) rate of 68.0% in 25 BCG-unresponsive NMIBC patients in Phase 2 ADVANCED-2 trial.","CR rate is consistent with the 68.2% announced on February 24, 2026, and meaningfully above 41.9% threshold.","Condition met for fixing termination date of April 2024 common stock warrants; exercisable at $5.25 through June 29, 2026.","Results from open-label trial; further updates may be required for regulatory discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103234,"accession_number":"0001213900-26-025432","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics Q4 net loss $17.3M; TARA-002 shows 68% CR in BCG-Unresponsive NMIBC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025: $17.3M ($0.37/share); FY2025: $57.4M ($1.34/share).","Cash $197.9M as of Dec 31, 2025; expects funding into 2028 after $86.3M December offering.","TARA-002 in BCG-Unresponsive NMIBC: 68.2% complete response at six months; no grade 3+ TRAEs.","FDA granted TARA-002 Breakthrough Therapy and Fast Track designations for lymphatic malformations.","Expects to complete BCG-Unresponsive cohort enrollment in 2H 2026; initiate ADVANCED-3 trial in 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103233,"accession_number":"0001213900-26-019617","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TARA-002 shows 68% CR at 6 months in BCG-unresponsive NMIBC; no Grade 3+ TRAEs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BCG-Unresponsive cohort: CR rate 68.2% at 6 months (15/22), 33.3% at 12 months (5/15); 61.5% re-induction conversion.","BCG-Naïve cohort: CR rate 66.7% at 6 months (18/27), 57.9% at 12 months (11/19); 66.7% re-induction conversion.","No Grade 3 or greater treatment-related adverse events; no discontinuations due to TRAEs; common TRAEs were dysuria (14%), bladder spasm (9%).","Enrollment completion of BCG-Unresponsive registrational cohort expected 2H 2026; ADVANCED-3 registrational trial for BCG-Naïve to start 2H 2026.","Data presented at ASCO GU 2026; company hosted conference call on Feb 24, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119483,"accession_number":"0001213900-25-121687","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protara closes full underwriters' option, gross proceeds ~$86.3M from offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed full exercise of underwriters' option for 1,956,521 shares at $5.75/share on Dec 15, 2025.","Combined with Dec 8 firm shares (13,043,479), total gross proceeds expected ~$86.3M.","Net proceeds to fund clinical development of TARA-002 and other programs.","Offering made under effective S-3 registration statement (File No. 333-275290)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119482,"accession_number":"0001213900-25-119242","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Protara Therapeutics prices public offering of 13M shares at $5.75 for $75M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 13,043,479 common shares at $5.75 per share; gross proceeds ~$75M before fees.","Underwriters granted 30-day option to buy up to 1,956,521 additional shares at same price.","Net proceeds to fund clinical development of TARA-002 and other pipeline programs.","Company and insiders subject to 60-day lock-up on share transfers post-offering.","Offering closed Dec 8, 2025; J.P. Morgan, TD Securities, Piper Sandler acted as representatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119481,"accession_number":"0001213900-25-117577","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protara reports 72% CR for TARA-002 in BCG-Naïve NMIBC; FDA backs registrational path","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CR at any time 72% (21/29); 69% at 6 months, 50% at 12 months in BCG-Naïve NMIBC.","No Grade 3+ treatment-related adverse events; no discontinuations due to TRAEs.","FDA agreed BCG not required as comparator; intravesical chemo acceptable for registrational trial.","On track for interim BCG-Unresponsive cohort data in Q1 2026; enrollment completion expected 2H 2026.","Re-induction salvaged 80% (4/5) non-responders; all maintained CR at 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119480,"accession_number":"0001213900-25-112383","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protara TARA-002 STARBORN-1: 100% clinical success in evaluable patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8/8 evaluable patients (100%) achieved clinical success at eight-week assessment.","80% (8/10) of patients that completed treatment achieved clinical success.","5/6 macrocystic patients had complete response; mixed cystic patient also complete response.","No serious adverse events; common AEs were swelling and fatigue; one discontinuation due to Grade 2 fatigue.","Two LMs patients reached 32-week post-treatment and remain disease-free."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119479,"accession_number":"0001213900-25-107873","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics Q3 net loss $13.3M; cash runway into mid-2027; key trial data readouts on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.3M ($0.31 per share) vs $11.2M ($0.50 per share) in Q3 2024.","Cash, equivalents and investments $133.6M as of Sept 30, expected to fund operations into mid-2027.","R&D expenses $9.6M, up $1.5M YoY driven by THRIVE-3 startup costs.","ADVANCED-2 interim data from ~25 BCG-Unresponsive NMIBC patients expected 1Q 2026.","STARBORN-1 interim update in pediatric LMs expected 4Q 2025; THRIVE-3 first patient dosing by year-end 2025."],"consensus_eps_estimate":-0.3917,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136046,"accession_number":"0001213900-25-073937","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Q2 net loss $15M; cash $145.6M into mid-2027; key trial readouts set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $15.0M ($0.35/shr) vs $9.5M ($0.45/shr) in Q2 2024; R&D spend up to $10.8M.","Cash, equivalents and investments $145.6M at June 30, expected to fund operations into mid-2027.","Interim data from ~25 BCG-unresponsive NMIBC patients (ADVANCED-2 trial) expected at 1Q 2026 medical conference.","First patient in THRIVE-3 Phase 3 registrational trial of IV Choline Chloride on track for 3Q 2025.","Appointed William Conkling as Chief Commercial Officer in June 2025; added to Russell 3000 Index."],"consensus_eps_estimate":-0.4131,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153082,"accession_number":"0001213900-25-053844","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protara Therapeutics stockholders elect directors and approve equity plan at 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders elected Luke Beshar, Roger Garceau, and Gregory Sargen as Class II directors with 17.7M, 22.1M, and 22.1M votes for, respectively.","Ratification of Ernst & Young as independent auditor for fiscal 2025 was approved with 29.3M votes for, 147,664 against, 327,362 abstentions.","Advisory vote on executive compensation passed with 20.4M for, 134,110 against, 2.1M abstentions, and 7.2M broker non-votes.","Amendment to the 2024 Equity Incentive Plan was approved with 21.3M for, 907,425 against, 365,697 abstentions, and 7.2M broker non-votes.","Over 38.5M shares were outstanding as of the April 16, 2025 record date; meeting held June 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153081,"accession_number":"0001213900-25-040809","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics Q1 2025 net loss $11.9M; TARA-002 100% CR in BCG-Unresponsive cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and investments total $157.5M as of Mar 31, 2025; expected to fund operations into 2027.","TARA-002 in BCG-Unresponsive NMIBC: 100% complete response (CR) at any time (5/5), 67% CR at 12 months (2/3) as of Apr 16, 2025.","Interim results from ~25 six-month evaluable BCG-Unresponsive patients expected by end of 2025; THRIVE-3 trial of IV Choline Chloride to start Q3 2025.","Appointed Leonardo Viana Nicacio, M.D., as CMO and Shane Williams, Ph.D., as VP, Head of HR/Chief People Officer in April 2025.","Net loss $11.9M ($0.29/sh) vs $11.1M ($0.97/sh) in Q1 2024; R&D expenses rose to $9.1M from $7.7M, G&A to $5.0M from $4.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153080,"accession_number":"0001213900-25-035785","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protara reports 100% CR at any time in BCG-unresponsive NMIBC; 67% at 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BCG-Unresponsive: 100% CR at any time (5/5), 67% at 12 months (2/3) as of April 16, 2025 cutoff.","BCG-Naïve: 76% CR at any time (16/21), 43% at 12 months (3/7) in Phase 2 ADVANCED-2 trial.","No Grade 3+ treatment-related adverse events; most AEs were Grade 1, transient, and consistent with immunopotentiation.","Company on track to present interim data from ~25 six-month evaluable BCG-Unresponsive patients by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171866,"accession_number":"0001213900-25-020366","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Q4 net loss $12.8M, cash $170M; ADVANCED-2 12-month data by mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $170.3M as of Dec 31, 2024, funded into 2027 after $100M public offering.","Full year 2024 net loss $44.6M ($2.17/share) vs $40.4M ($3.57/share) in 2023.","ADVANCED-2 trial: 12-month data from evaluable NMIBC patients expected by mid-2025; 72% CR at 6 months reported.","THRIVE-3 registrational trial of IV Choline Chloride to start in 1H 2025; FDA Fast Track granted.","STARBORN-1 interim update for TARA-002 in pediatric LMs expected by end of 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171865,"accession_number":"0001213900-25-003026","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protara reports positive TARA-002 NMIBC data; expects key milestones in 2025; cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TARA-002 in NMIBC: 72% CR at six months, 70% at any time; 100% maintained CR from 3 to 6 months; no Grade 2+ TRAEs.","Expects 12-month evaluable data mid-2025 and futility analysis of ~25 BCG-unresponsive patients by end 2025.","Expects to start THRIVE-3 registrational trial of IV Choline Chloride in 1H 2025; FDA Fast Track granted.","TARA-002 in LMs: initial results from additional STARBORN-1 cohorts expected by end of 1H 2025.","Cash of $81.5M plus ~$100M gross from December offering (including partial option exercise) funds operations into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188864,"accession_number":"0001213900-24-107906","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Protara Therapeutics raises $100M in public offering to fund TARA-002 clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$100M from offering of 13.69M shares and 2.33M pre-funded warrants at $6.25/share.","Proceeds to fund clinical development of TARA-002 for cancer and rare diseases; also working capital.","Underwriters granted 30-day option to purchase up to 2.4M additional shares; company and insiders have 60-day lock-up.","Offering closed December 11, 2024; TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., Scotiabank acted as joint book-runners.","Pre-funded warrants exercisable at $0.001, with ownership limitation of 4.99% (adjustable to 19.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188863,"accession_number":"0001213900-24-105782","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protara TARA-002 shows 72% CR at 6 months in NMIBC Phase 2; 100% in BCG-unresponsive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["72% (13/18) landmark complete response rate at 6 months across BCG exposures; 70% (14/20) at any time.","In BCG-unresponsive pivotal cohort: 100% (4/4) CR at 6 months; 80% (4/5) at any time.","Favorable safety: no Grade 2+ treatment-related AEs; no discontinuations due to AEs; majority Grade 1 and transient.","100% (9/9) maintained CR from 3 to 6 months; 80% (4/5) re-induction salvage rate.","Plans to report initial 12-month evaluable patient data in mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188862,"accession_number":"0001213900-24-096243","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics reports Q3 2024 net loss of $11.2M; cash $81.5M; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.2M ($0.50 per share) vs $9.9M ($0.87) in Q3 2023; no revenue.","Cash, equivalents, and investments $81.5M as of Sept 30; sufficient to fund operations into 2026.","R&D expenses $8.1M; G&A $4.3M; stock-based comp $0.9M.","On track to report interim 6-month data from TARA-002 in NMIBC ADVANCED-2 trial in 4Q 2024.","FDA Fast Track granted for IV Choline Chloride; THRIVE-3 first patient dosing expected in 1Q 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205340,"accession_number":"0001213900-24-065378","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics Q2 net loss $9.5M; cash $89.6M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.5M ($0.45/share) vs $11.3M ($1.00/share) in Q2 2023; R&D expenses decreased to $6.4M.","Cash and investments $89.6M at June 30, including $42M net from April private placement; funding expected into 2026.","Expects preliminary data from 6-month evaluable patients in ADVANCED-2 trial (TARA-002 in NMIBC) in Q4 2024.","Pivotal trial dosing for IV Choline Chloride in PN patients expected to begin Q1 2025 after FDA alignment.","Appointed Lisa Schlesinger as VP, Head of New Product Development and Market Access in June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222233,"accession_number":"0001213900-24-051210","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protara Therapeutics stockholders approve all five proposals at 2024 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors elected: Jane Huang (9.66M for), Richard Levy (9.64M for), Michael Solomon (9.56M for); broker non-votes 3.81M.","Ratification of Ernst & Young as auditor: 13.40M for, 189,574 against, 1,424 abstentions.","Advisory vote on exec compensation approved: 7.00M for, 196,457 against, 2.59M abstentions plus broker non-votes.","2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan both approved: 9.60M and 9.65M for, respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222232,"accession_number":"0001213900-24-038756","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics Q1 net loss $11.1M; cash runway into 2026 after $42M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $11.1M ($0.97/sh) vs $9.0M ($0.80/sh) YoY; R&D spend rose to $7.7M from $5.1M.","Cash, equivalents and marketable securities $55.2M at Mar 31, 2024; combined with $42M net from April PIPE funds operations into 2026.","TARA-002 in NMIBC: 3-month CR rate 38% overall; 63% in CIS-only; no Grade 3+ related AEs.","ADVANCED-2 interim data (BCG-unresponsive/naïve) expected 2H 2024; registrational path aligned with FDA guidance.","FDA aligned on registrational path for IV Choline Chloride as choline source for PN-dependent patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222231,"accession_number":"0001213900-24-030623","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Protara raises ~$45M in private placement; reports positive TARA-002 data and FDA alignment for IV Choline Chloride","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement: gross proceeds ~$45M from 9.14M shares and 1.7M pre-funded warrants at $4.15; common warrants exercisable at $5.25.","FDA alignment on registrational path for IV Choline Chloride in PN patients; Phase 2b/3 THRIVE-3 to start in 1H 2025.","TARA-002 three-month CR 38% (6/16) in NMIBC; 63% in CIS-only; 43% in BCG-Unresponsive/Experienced; no Grade 3+ treatment-related AEs.","ADVANCED-2 Phase 2 trial adds 80 KE dose cohort and systemic priming; six-month data expected 2H 2024; plans TARA-002 + pembrolizumab combo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241753,"accession_number":"0001213900-24-023589","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Protara CMO Jathin Bandari resigns effective April 11; interim oversight assigned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Jathin Bandari resigns effective April 11, 2024 to explore academic opportunities; consulting through July 11.","Severance includes $365,386 lump sum (9 months salary), $164,424 bonus, COBRA for 9 months, and pro-rata vesting of 11,993 options + 5,886 RSUs.","Interim oversight: Jacqueline Zummo (SVP & Chief Scientific Ops Officer) leads medical staff, advised by board member Richard Levy, M.D.","Company plans to search for a new Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241752,"accession_number":"0001213900-24-021981","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara reports Q4 net loss of $10.2M; cash $65.6M; TARA-002 data milestones in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023: $10.2M ($0.90/share); full-year net loss $40.4M ($3.57/share).","Cash, equivalents & investments $65.6M as of Dec 31, 2023; runway into Q2 2025.","R&D expenses Q4 $6.4M (up from $5.0M YoY); full-year $25.0M (up from $16.8M).","Preliminary ADVANCED-1EXP TARA-002 data in NMIBC CIS expected 1H 2024; ADVANCED-2 data in 2H 2024.","Dosing underway in STARBORN-1 Phase 2 trial of TARA-002 for lymphatic malformations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259193,"accession_number":"0001213900-23-083011","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Q3 net loss $9.9M; cash $74M; TARA-002 trials advance with results expected 1H24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 net loss of $9.9M ($0.87/shr) vs $7.7M ($0.68/shr) in Q3 2022.","Cash, cash equivalents & investments of $74.0M as of Sept 30, expected to fund ops into Q2 2025.","R&D expenses rose to $6.2M from $3.5M, driven by TARA-002 clinical trial activities.","First patient dosed in Phase 2 ADVANCED-2 (NMIBC) and Phase 2 STARBORN-1 (lymphatic malformations) trials.","Preliminary results from ADVANCED-1EXP expansion trial in NMIBC on track for 1H24."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276470,"accession_number":"0001213900-23-062780","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Q2 net loss $11.3M; TARA-002 trials on track; cash runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2023: $11.3M ($1.00/share) vs $8.5M ($0.76) in Q2 2022","Cash, equivalents $80.4M; expected to fund operations into 2025","R&D expenses $7.2M, up from $3.1M YoY on TARA-002 clinical costs","Preliminary TARA-002 NMIBC expansion results expected 1H24; ADVANCED-2 and LM trial start 4Q23"],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294206,"accession_number":"0001213900-23-047460","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protara Therapeutics annual meeting: all proposals approved by shareholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors elected: Shefferman 5.68M for, Flannelly 5.63M, Smith 5.66M; 2.26M broker non-votes each.","Ratification of Ernst & Young as auditor passed: 8.16M for, 29,326 against, 709 abstentions.","Advisory vote on named executive officer compensation approved: 5.57M for, 296,338 against, 62,576 abstentions.","Record date April 11, 2023; 11,307,962 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294205,"accession_number":"0001213900-23-036112","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara reports Q1 net loss $9.0M; plans Phase 2 trials for TARA-002 in NMIBC and LMs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and restricted cash $89.5M at March 31, 2023; funding expected into 2025.","Net loss $9.0M ($0.80/sh) vs $10.8M ($0.96) in Q1 2022; R&D $5.1M, G&A $4.6M.","Positive preliminary data: TARA-002 well tolerated; tumor regression in all 3 evaluable CIS patients, including a CR in a BCG-unresponsive patient.","ADVANCED-2 Phase 1b/2 trial in up to 102 CIS patients planned for 2H23; STARBORN-1 Phase 2 in pediatric LMs cleared by FDA, start Q4 2023.","IV Choline Chloride IFALD prospective study ongoing; results expected Q3 2023, then regulatory feedback."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294204,"accession_number":"0001213900-23-035154","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protara gets FDA clearance to start Phase 2 STARBORN-1 trial of TARA-002 for pediatric lymphatic malformations","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared the Phase 2 STARBORN-1 trial of TARA-002 (cell-based immunopotentiator) in pediatric patients with lymphatic malformations.","Trial is single-arm, open-label, enrolling ~30 patients aged 6 months to <18 years; primary endpoint is clinical success (≥60% volume reduction).","TARA-002 previously granted Rare Pediatric Disease designation by FDA; trial initiation expected in Q4 2023.","Predecessor therapy OK-432 is approved in Japan and Taiwan and was studied in a U.S. compassionate-use program of over 500 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294203,"accession_number":"0001213900-23-033507","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Protara reports positive Phase 1a data for TARA-002 in NMIBC; plans Phase 2 trial in 2H2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TARA-002 well tolerated at all three doses; no dose-limiting toxicities; 40KE dose selected for further trials.","Of 3 evaluable CIS patients, 1 heavily pre-treated BCG-unresponsive patient achieved complete response; tumor regression in other 2.","ADVANCED-2 Phase 1b/2 trial to enroll up to 102 CIS patients (BCG-naïve and BCG-unresponsive) starting 2H2023.","Company expects current resources to fund operations into 2025, supporting clinical plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314816,"accession_number":"0001213900-23-019281","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Protara confirms no material SVB exposure; cash runway into 2025 unchanged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$102.3M cash equivalents invested in short-term treasury/corporate bonds, not SVB.","Operating account at SVB used only for monthly expenses; minimal balance.","Company does not expect SVB failure to impact operations or liquidity.","Reiterates cash runway guidance into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314815,"accession_number":"0001213900-23-018371","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Q4 net loss $39.0M; cash $102.3M; TARA-002 data expected Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022: $39.0M ($3.46 per share) vs $10.2M ($0.91) in Q4 2021; includes $29.5M goodwill impairment.","Full year 2022 net loss $66.0M ($5.86 per share) vs $47.3M ($4.21) in 2021; R&D expense $16.8M, G&A $20.7M.","Cash, equivalents, and marketable debt securities $102.3M as of Dec 31, 2022; expected to fund operations into 2025.","Phase 1a data from ADVANCED-1 trial of TARA-002 in NMIBC expected in Q2 2023; Phase 2 trial in LMs to start 2H 2023.","Prospective study of IV Choline Chloride in IFALD ongoing; results expected Q3 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314814,"accession_number":"0001213900-23-005811","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-01-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Protara Therapeutics appoints Patrick Fabbio as CFO effective Jan 30, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Fabbio appointed CFO, replacing interim CFO Jesse Shefferman (CEO).","Fabbio brings 30+ years life science finance experience; most recently President & CFO of Rafael Holdings.","Compensation: $445k base salary, 45% target bonus, $25k signing bonus, 300k stock option (4-yr vest).","Severance: without cause/good reason → 9 months base + 12 months target bonus + 9 months healthcare.","On change-in-control termination within 12 months: 100% equity acceleration, 12 months base salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":314813,"accession_number":"0001213900-23-001140","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Protara Therapeutics posts corporate presentation; content not detailed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation filed as Exhibit 99.1 and posted on IR page on January 5, 2023.","Intended for use at investor meetings; no financial results or new pipeline data disclosed.","No specific forward-looking statements or material events included in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333194,"accession_number":"0001213900-22-068819","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Q3 net loss $7.7M; cash $107.1M; TARA-002 trials progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.7M ($0.68/share) vs. $10.8M ($0.96) in Q3 2021; includes $1.4M stock-based compensation.","Cash and investments $107.1M as of Sep 30, 2022; expected to fund operations into 2H2024.","R&D expense $3.5M, down from $4.1M; G&A $4.5M, down from $6.7M year-over-year.","Phase 1a dose escalation of TARA-002 in NMIBC ongoing; Phase 2 in LMs expected to start in 2023 after FDA feedback.","IV Choline Chloride IFALD study ongoing; results to inform next steps."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350666,"accession_number":"0001213900-22-045601","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics Q2 2022 net loss $8.5M ($0.80/share); cash $112.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.5M ($0.80 per share) vs $12.8M ($1.14) in Q2 2021.","Cash, cash equivalents and marketable debt securities of $112.8M as of June 30, 2022.","R&D expenses decreased to $3.1M from $5.9M; G&A decreased to $5.6M from $6.9M.","ADVANCED-1 Phase 1 trial of TARA-002 in NMIBC enrollment progressing; Trials in Progress poster presented at ASCO June 2022.","EMA granted orphan drug designation to TARA-002 for lymphatic malformations; Phase 2 trial planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350665,"accession_number":"0001213900-22-039976","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2022-07-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Protara Therapeutics appoints Hannah Fry as Controller and CEO as principal financial officer after CFO departure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Blaine Davis departed as CFO on July 15, 2022.","Hannah Fry appointed Controller effective July 16, 2022, with $255,000 base salary and 25,000 RSU award.","CEO Jesse Shefferman appointed as principal financial officer of the company.","Fry's severance includes six months base salary and pro-rata equity vesting on certain awards.","Fry previously served as Senior Director, Assistant Controller at Protara."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367863,"accession_number":"0001213900-22-033756","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Protara Therapeutics CFO Blaine Davis to depart July 15, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Blaine Davis leaving to pursue other opportunities, effective July 15, 2022; resignation not due to disagreements.","Separation agreement: 12-month base salary lump sum, target bonus, COBRA and life insurance premiums, accelerated equity vesting.","Company had $119M cash, cash equivalents and investments as of March 31, 2022, expected to fund operations into mid-2024.","CEO Jesse Shefferman thanked Davis for building finance, commercial, and IT functions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367862,"accession_number":"0001213900-22-031985","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2022-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Protara Therapeutics shareholders elect three directors, ratify auditor, approve say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Luke Beshar, Roger Garceau, and Gregory Sargen as Class II directors to serve until 2025 annual meeting.","Ratified Ernst & Young as independent registered public accounting firm for fiscal year ending Dec 31, 2022 with 8,385,650 votes for.","Advisory vote approved compensation of named executive officers with 6,426,881 votes for, 126,276 against, 54,902 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":367861,"accession_number":"0001213900-22-024098","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics Q1 2022 net loss narrows to $10.8M; cash $118.5M funds into mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.8M ($0.96/share) versus $13.5M ($1.20/share) in Q1 2021.","Cash and equivalents $118.5M as of March 31, 2022; expected to fund operations into mid-2024.","Phase 1 ADVANCED-1 trial of TARA-002 for NMIBC first patient dosed in March 2022.","FDA preliminary guidance received for TARA-002 in lymphatic malformations; Phase 2 trial planning underway.","U.S. patent issued for IV Choline Chloride composition with term expiring in 2041."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387191,"accession_number":"0001213900-22-011205","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics reports Q4 net loss of $10.2M; cash $130.7M funds operations into mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2021 was $10.2M ($0.91 loss per share); full year net loss $47.3M ($4.21 loss per share).","Cash and marketable securities $130.7M as of Dec 31, 2021; expected to fund operations into mid-2024.","R&D expenses rose to $4.1M in Q4 (vs $3.7M prior year) and $21.1M for full year (vs $12.0M).","Phase 1 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) has commenced after FDA IND clearance.","Jathin Bandari, M.D., appointed as Chief Medical Officer in January 2022; previously Interim CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387190,"accession_number":"0001213900-22-001222","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Protara Therapeutics appoints Jathin Bandari as Chief Medical Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Bandari, previously Interim CMO, appointed permanent CMO effective Jan 10, 2022.","Annual base salary of $415,000, discretionary bonus target 40% of base.","Granted stock option for 81,000 shares and RSU for 13,500 shares, subject to board approval.","Severance: 9 months salary plus target bonus and healthcare if terminated without cause or for good reason.","In change of control termination, 100% acceleration of unvested equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405132,"accession_number":"0001213900-21-056585","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Therapeutics reports Q3 2021 net loss of $10.8M; FDA clears IND for TARA-002 in NMIBC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $10.8M ($0.96/sh) vs $8.0M ($1.26/sh) in Q3 2020; R&D expense $4.1M (up from $2.8M), G&A $6.7M (up from $5.3M).","Cash, equivalents and marketable debt securities $138.4M as of Sept 30, 2021.","FDA cleared IND for TARA-002 in non-muscle invasive bladder cancer; Phase 1 trial start planned by year-end 2021.","Hired Mary Grendell (ex-Intercept Pharmaceuticals) as General Counsel; completed GMP comparability for TARA-002."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405131,"accession_number":"0001213900-21-053303","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2021-10-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Protara Therapeutics CMO Departs; Jathin Bandari Named Interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martín Sebastian Olivo, M.D., left as Chief Medical Officer effective Oct 15, 2021; will serve as consultant through Nov 22, 2021.","Jathin Bandari, M.D., promoted to VP, Head of Clinical Development and Interim Chief Medical Officer.","Severance includes nine months base salary lump sum, pro-rata bonus, COBRA reimbursement, and pro-rata equity vesting.","Dr. Bandari joined Protara in April 2020; is a urologic oncologist with fellowship at University of Pittsburgh Medical Center."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405130,"accession_number":"0001213900-21-052250","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2021-10-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Protara Therapeutics receives FDA IND clearance for TARA-002 in non-muscle invasive bladder cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for TARA-002, an investigational cell-based therapy for NMIBC.","Phase 1 trial planned to initiate by year-end 2021 in high-grade NMIBC patients.","TARA-002 manufactured from same cell bank as OK-432, approved in Japan and Taiwan.","Confirmatory GMP-scale comparability data submitted and reviewed by FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424162,"accession_number":"0001213900-21-040412","cik":1359931,"company_name":"Protara Therapeutics, Inc.","ticker":"TARA","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Protara Q2 net loss $12.8M; cash $145M; on track for TARA-002 IND by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $145M; net loss $12.8M ($1.14/sh) vs $7.1M ($1.22/sh) in Q2 2020.","R&D expense rose to $5.9M (from $2.5M) on TARA-002; G&A $6.9M (from $4.8M).","Completed IND-enabling studies for TARA-002 in NMIBC; on track to file IND H2 2021 & start Phase 1.","GMP comparability for TARA-002 on track for year-end; seeking FDA alignment on LM trial design.","Appointed Dr. Jane Huang (BeiGene CMO) to Board of Directors in June 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":268094232.41596636,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}